ATE297731T1 - Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol - Google Patents
Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinolInfo
- Publication number
- ATE297731T1 ATE297731T1 AT99911307T AT99911307T ATE297731T1 AT E297731 T1 ATE297731 T1 AT E297731T1 AT 99911307 T AT99911307 T AT 99911307T AT 99911307 T AT99911307 T AT 99911307T AT E297731 T1 ATE297731 T1 AT E297731T1
- Authority
- AT
- Austria
- Prior art keywords
- alzheimer
- disease
- treatment
- clioquinol
- metal chelators
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 3
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 title 1
- 239000002738 chelating agent Substances 0.000 title 1
- 229960005228 clioquinol Drugs 0.000 title 1
- 239000002184 metal Substances 0.000 title 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 230000006950 reactive oxygen species formation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/038,154 US6323218B1 (en) | 1998-03-11 | 1998-03-11 | Agents for use in the treatment of Alzheimer's disease |
| PCT/US1999/005291 WO1999045907A2 (en) | 1998-03-11 | 1999-03-11 | Metal chelators for use in the treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE297731T1 true ATE297731T1 (de) | 2005-07-15 |
Family
ID=21898356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99911307T ATE297731T1 (de) | 1998-03-11 | 1999-03-11 | Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6323218B1 (de) |
| EP (1) | EP1061923B1 (de) |
| JP (1) | JP2002506020A (de) |
| AT (1) | ATE297731T1 (de) |
| AU (1) | AU752236B2 (de) |
| CA (1) | CA2323458C (de) |
| DE (1) | DE69925816T2 (de) |
| WO (1) | WO1999045907A2 (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6743771B2 (en) * | 1995-12-29 | 2004-06-01 | Novactyl, Inc. | Methods and compositions for controlling protein assembly or aggregation |
| US7045531B1 (en) * | 1997-03-11 | 2006-05-16 | The General Hospital Corporation | Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator |
| US20020025944A1 (en) * | 2000-04-28 | 2002-02-28 | Bush Ashley I. | Use of clioquinol for the therapy of Alzheimer's disease |
| US20050112543A1 (en) * | 1998-03-11 | 2005-05-26 | The General Hospital Corporation | Method of screening for drugs useful in treating Alzheimer's disease |
| US6323218B1 (en) * | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
| WO2000018392A1 (en) | 1998-09-25 | 2000-04-06 | Glycox Corporation Limited | Fructosamine oxidase: antagonists and inhibitors |
| DE19909357A1 (de) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
| US20040110722A1 (en) * | 1999-05-27 | 2004-06-10 | Ornberg Richard L. | Modified hyaluronic acid polymers |
| ES2240101T3 (es) * | 1999-05-27 | 2005-10-16 | Monsanto Company | Biomateriales modificados con mimeticos de superoxido dismutasa. |
| AUPQ180499A0 (en) * | 1999-07-23 | 1999-08-19 | Biomolecular Research Institute Limited | Beta-amyloid peptide inhibitors |
| CA2384458A1 (en) * | 1999-09-23 | 2001-03-29 | Chroma Graphics, Inc. | Method and apparatus for describing and simulating complex systems |
| US7592304B2 (en) | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| FR2818551B1 (fr) * | 2000-12-22 | 2007-06-01 | Claude Marc Pierre Hannoun | Utilisation de chelateurs pour le traitement des maladies a prions |
| EP2500018B1 (de) | 2002-03-08 | 2017-07-19 | PhilERA New Zealand Limited | Verhindern und/oder Behandeln der kardiovaskulären Erkrankung und/oder zugehöriges Herzversagen |
| DE10221052A1 (de) * | 2002-05-10 | 2003-12-04 | Transmit Technologietransfer | Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten |
| US6855340B2 (en) * | 2002-05-24 | 2005-02-15 | Regents Of The University Of Michigan | Copper lowering treatment of inflammatory and fibrotic diseases |
| US20070248689A1 (en) * | 2002-05-24 | 2007-10-25 | Regents Of The University Of Michigan | Copper lowering treatment of inflammatory and fibrotic diseases |
| US20040086511A1 (en) * | 2002-07-12 | 2004-05-06 | The Johns Hopkins University | Neuronal gene expression patterns |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| MXPA05001758A (es) * | 2002-08-16 | 2005-08-19 | Wyeth Corp | Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage). |
| US20060100278A1 (en) | 2002-08-20 | 2006-05-11 | Cooper Garth J S | Dosage forms and related therapies |
| AU2004206956A1 (en) * | 2003-01-22 | 2004-08-05 | The General Hospital Corporation | Amyloid-binding, metal-chelating agents |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| CN1805743A (zh) * | 2003-05-20 | 2006-07-19 | 特兰斯泰克制药公司 | 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂 |
| CA2546064C (en) * | 2003-11-12 | 2011-06-21 | Lead Chemical Co., Ltd. | Percutaneous absorption type cerebral protective agent |
| CA2550505A1 (en) * | 2003-12-19 | 2005-06-30 | Protemix Corporation Limited | Copper antagonist compounds |
| EP1778618B1 (de) | 2004-07-19 | 2013-12-25 | PhilERA New Zealand Limited | Synthese von triethylenetetraminen |
| ES2473587T3 (es) | 2004-08-03 | 2014-07-07 | Transtech Pharma, Inc. | Proteínas de fusión de RAGE y métodos de uso |
| EP1776459A1 (de) * | 2004-08-03 | 2007-04-25 | Transtech Pharma, Inc. | Rage-fusionsproteine und verfahren zu ihrer verwendung |
| WO2006041874A2 (en) * | 2004-10-04 | 2006-04-20 | Myriad Genetics, Inc. | Compounds for alzheimer's disease |
| EP1854482A4 (de) * | 2005-01-31 | 2010-08-11 | Riken | Mittel zur kontrolle der degranulationsreaktion und zytokin-produktion |
| EP1948160A4 (de) * | 2005-11-09 | 2013-07-10 | Protemix Corp Ltd | Behandlung von mitochondrien-bedingten erkrankungen und verbesserung von altersbedingten stoffwechseldefiziten |
| PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| EP1963786B1 (de) * | 2005-12-23 | 2013-07-24 | GCoder Systems AB | Positionierungsmuster |
| WO2007094926A2 (en) * | 2006-02-09 | 2007-08-23 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
| US20130178536A1 (en) * | 2006-04-25 | 2013-07-11 | Stc.Unm | Substituted cis- and trans-stilbenes as therapeutic agents |
| EA017291B1 (ru) | 2006-05-05 | 2012-11-30 | Транстек Фарма, Инк. | Белки слияния на основе rage, их композиции и способы их применения |
| US8338089B2 (en) * | 2006-11-20 | 2012-12-25 | The Johns Hopkins University | Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
| US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8398977B2 (en) | 2007-06-14 | 2013-03-19 | Galactica Pharmaceuticals, Inc. | Rage fusion proteins |
| US20090131857A1 (en) * | 2007-11-20 | 2009-05-21 | Mark Geiger | Method and apparatus for introducing a medicinal dose directly into a mammalian patient's cerebrospinal fluid |
| US9034341B2 (en) | 2009-04-20 | 2015-05-19 | Transtech Pharma, Llc | Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions |
| CA2772797C (en) | 2009-09-30 | 2018-09-25 | Transtech Pharma, Inc. | Substituted imidazole derivatives |
| WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| KR20150064743A (ko) | 2012-10-05 | 2015-06-11 | 트랜스테크 파르마 엘엘씨 | 경도 및 중등도 알츠하이머 병의 치료 |
| WO2016005992A1 (en) * | 2014-07-11 | 2016-01-14 | Council Of Scientific And Industrial Research | SUBSTITUTED NAPHTHO[2,1-b][1,10]PHENANTHROLINE BASED FLUORESCENT DYES AND APPLICATION THEREOF |
| WO2019067782A1 (en) * | 2017-09-28 | 2019-04-04 | University Of Massachusetts | COMBINED TREATMENT OF NEUROPSYCHIATRIC DISORDERS |
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| JP7464591B2 (ja) | 2018-10-10 | 2024-04-09 | ブイティーブイ・セラピューティクス・エルエルシー | [3-(4-{2-ブチル-1-[4-(4-クロロ-フェノキシ)-フェニル]-1h-イミダゾール-4-イル}-フェノキシ)-プロピル]-ジエチル-アミンの代謝産物 |
| USD1121577S1 (en) * | 2023-05-01 | 2026-04-07 | Wolfspeed, Inc. | Power package |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5110493A (en) | 1987-09-11 | 1992-05-05 | Syntex (U.S.A.) Inc. | Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant |
| US5677330A (en) | 1990-02-12 | 1997-10-14 | The Center For Innovative Technology | Medical uses of allosteric hemoglobin modifier compounds in patient care |
| WO1994004167A1 (en) | 1991-02-26 | 1994-03-03 | THE UNITED STATES OF AMERICA represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES | Metal-based formulations with high microbicidal efficiency valuable for disinfection and sterilization |
| GB9108080D0 (en) | 1991-04-15 | 1991-06-05 | Smithkline Beecham Plc | Pharmaceutical composition |
| US5434050A (en) | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
| US5206264A (en) | 1991-11-04 | 1993-04-27 | Cypros Pharmaceutical Corporation | Use of disulfiram to prevent cardiovascular damage |
| GB9123937D0 (en) * | 1991-11-11 | 1992-01-02 | Framo Dev Ltd | Metering device for a multiphase fluid flow |
| DE69227380T3 (de) | 1991-11-12 | 2007-01-11 | Prana Biotechnology Ltd., South Melbourne | Verfahren zur bestimmung und behandlung von alzheimer-krankheit |
| US5466680A (en) * | 1992-03-26 | 1995-11-14 | Cytologics, Inc. | Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
| GB9211779D0 (en) | 1992-06-03 | 1992-07-15 | Ciba Geigy Ag | Amine salts |
| US5357636A (en) * | 1992-06-30 | 1994-10-25 | Dresdner Jr Karl P | Flexible protective medical gloves and methods for their use |
| US5688516A (en) | 1992-11-12 | 1997-11-18 | Board Of Regents, The University Of Texas System | Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices |
| US5840739A (en) | 1992-11-16 | 1998-11-24 | University Of Florida Research Foundation, Inc. | Thiazoline acid derivatives |
| AU6580494A (en) | 1994-05-11 | 1995-12-05 | P.N. Gerolymatos S.A. | Use of clioquinol for treating helicobacter, including (h. pylori), infections and related diseases |
| US5688651A (en) | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| CA2214247C (en) | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| WO1997009976A2 (en) | 1995-09-01 | 1997-03-20 | Washington University | Method of reducing neurotoxic injury with zinc chelators |
| PT959888E (pt) * | 1996-08-13 | 2002-02-28 | Gerolymatos P N Sa | Utilizacao do agente quelante clioquinol para o fabrico de uma composicao farmaceutica para o tratamento de doenca de alzheimer |
| DE19648272A1 (de) * | 1996-11-21 | 1998-05-28 | Emitec Emissionstechnologie | Verfahren und Vorrichtung zur Bestimmung einer Zelldichte eines Wabenkörpers, insbesondere für einen Abgaskatalysator |
| EP1007048A4 (de) * | 1997-03-11 | 2004-09-22 | Gen Hospital Corp | Identifizierung von mitteln zur behandlung der alzheimerischen krankheit |
| IL134263A (en) | 1997-08-21 | 2006-04-10 | Gerolymatos P N Sa | Pharmaceutical compositions containing phanquinone for the treatment of alzheimer's disease |
| US5980914A (en) * | 1997-08-22 | 1999-11-09 | P.N. Gerolymatos S.A. | Clioquinol for the treatment of Parkinson's disease |
| JP2001519529A (ja) | 1997-10-06 | 2001-10-23 | ザ ジェネラル ホスピタル コーポレイション | 遅発性ジスキネジーを予測するために薬物をスクリーニングするための方法 |
| US5994323A (en) * | 1997-12-31 | 1999-11-30 | P.N. Gerolymatos S.A. | Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof |
| US6323218B1 (en) * | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
-
1998
- 1998-03-11 US US09/038,154 patent/US6323218B1/en not_active Expired - Fee Related
-
1999
- 1999-03-11 EP EP99911307A patent/EP1061923B1/de not_active Expired - Lifetime
- 1999-03-11 CA CA002323458A patent/CA2323458C/en not_active Expired - Fee Related
- 1999-03-11 DE DE69925816T patent/DE69925816T2/de not_active Expired - Fee Related
- 1999-03-11 AT AT99911307T patent/ATE297731T1/de not_active IP Right Cessation
- 1999-03-11 JP JP2000535322A patent/JP2002506020A/ja active Pending
- 1999-03-11 WO PCT/US1999/005291 patent/WO1999045907A2/en not_active Ceased
- 1999-03-11 AU AU29981/99A patent/AU752236B2/en not_active Ceased
-
2001
- 2001-09-21 US US09/956,980 patent/US20020082273A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20020082273A1 (en) | 2002-06-27 |
| EP1061923B1 (de) | 2005-06-15 |
| WO1999045907A2 (en) | 1999-09-16 |
| EP1061923A2 (de) | 2000-12-27 |
| CA2323458C (en) | 2008-01-29 |
| WO1999045907A9 (en) | 2000-11-09 |
| JP2002506020A (ja) | 2002-02-26 |
| WO1999045907A3 (en) | 2000-04-06 |
| DE69925816D1 (de) | 2005-07-21 |
| HK1033907A1 (en) | 2001-10-05 |
| DE69925816T2 (de) | 2005-12-22 |
| CA2323458A1 (en) | 1999-09-16 |
| AU2998199A (en) | 1999-09-27 |
| AU752236B2 (en) | 2002-09-12 |
| US6323218B1 (en) | 2001-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69925816D1 (de) | Metall chelatoren zur verwendung in der behandlung von alzheimers erkrankung mit clioquinol | |
| DE69914726D1 (de) | Zusammensetzung zur regulierung des hauterscheinungsbildes | |
| ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| DE60116313D1 (de) | Verbindungen zur behandlung der alzheimerischen krankheit | |
| DE69932645D1 (de) | Neue Fettsäureanaloge zur Behandlung der Fettleber | |
| DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| ATE450515T1 (de) | Anilinopyrimidinderivate als ikk?inhibitoren, und hiermit in zusammenhang stehende zusammensetzungen und verfahren | |
| ATE283032T1 (de) | Formulierungen und verfahren zur verminderung von hautirritationen | |
| ATE371475T1 (de) | Methoden zur behandlung der hautpigmentierung | |
| DE60112055D1 (de) | Inhibitoren von gamma-secretase | |
| DE60117605D1 (de) | Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie | |
| CA2284170A1 (en) | Identification of agents for use in the treatment of alzheimer's disease | |
| WO2002002512A3 (en) | Compounds to treat alzheimer's disease | |
| DE60226729D1 (de) | Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| DE69728594T2 (de) | Chromfreie Zusammensetzung für die Behandlung von metallischen Oberflächen | |
| ES2184077T3 (es) | Nuevas fenantridinas sustituidas en la posicion 6. | |
| DE69902154D1 (de) | Eisen-dextran verbindung zur verwendung als komponente in einer therapeutischen zusammensetzung zur behandlung oder prophylaxe von eisenmangel, sowie verfahren zur herstellung der eisen-dextran verbindung und ihre anwendung zur herstellung einer parenteral anwendbaren therapeutischen zubereitung. | |
| DE60013098D1 (de) | Zusammensetzung zur hautdesinfizierung | |
| DE69519577D1 (de) | Prednisolonmetasulfobenzoatzusammensetzung zur behandlung von entzündungserkrankung des darmes | |
| DK1077941T3 (da) | Forbindelser med væksthormonfrigörende egenskaber | |
| NO20054744L (no) | Behandling av Alzheimers sykdom | |
| ATE446285T1 (de) | Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3- thiosubstituierte indol-2-alkinsäuren | |
| ATE418552T1 (de) | Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
| ATE188869T1 (de) | Stabilisiertes sonnenschutzmittel | |
| DE69924676D1 (de) | Rotor zur Behandlung von geschmolzenem Metall |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |